非小细胞肺癌分子靶向治疗及其耐药

Molecular targeted therapy for non-small cell lung cancer and drug resistance

以吉非替尼和厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗中发挥重要作用,然而在临床前和临床研究中发现,许多患者对此类药物存在原发性耐药或获得性耐药,使其临床应用受到一定限制.目前许多研究致力于延缓、逆转耐药以及开发新的靶点,为非小细胞肺癌的靶向治疗提供了更多的可能.

Gefitinib and erlotinib play important roles, which as the representative of the epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer （NSCLC）.However, preclinical and clinical studies find that many patients exist primary or acquired drug resistance to this drug, which limits the use of molecular targeted therapy drugs.At present, there are many studies focus on delaying or reversing drug resistance and developing new targets, which provide more potential for the molecular targeted therapy of NSCIC.